Clinical trials: Airflow Limitation
Chronic Obstructive Pulmonary Disease (COPD)
A Multi-centre Randomized Double Blind 52-week Study to Assess the Safety of QVA149 Compared to QAB149 in Patients With COPD Who Have Moderate to Severe Airflow Limitation
This study is to assess the safety and tolerability of two different doses of QVA149 and QAB149 in patients with moderate to severe airflow limitation.
- Trial name
- NCT01682863
- Testing
- QVA149, QAB149
- Where
- 86 sites in United States, Bulgaria and 5 more
- Volunteers
- 614 people
- Sponsor
- Novartis Pharmaceuticals
Pulmonary Disease, Chronic Obstructive
Investigation of Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Efficacy of Oral Danirixin in Symptomatic COPD Subjects With Mild to Moderate Airflow Limitation at Risk for Exacerbations
The aim of this First Time in Patient study is to obtain initial information on the safety, tolerability, pharmacokinetics, pharmacodynamics and clinical efficacy of repeat daily administration of danirixin in subjects with…
- Trial name
- NCT02130193
- Testing
- Danirixin
- Where
- 16 sites in United States, Germany
- Volunteers
- 102 people
- Sponsor
- GlaxoSmithKline
Bronchiectasis Adult
Efficacy and Safety of Inhaled Bronchodilator in Non-CF Bronchiectasis With Airflow Limitation
Airflow limitation is common exist in idiopathic bronchiectasis patients. However, there are few evidence on the treatment of bronchodilator in bronchiectasis with airflow limitation.
- Trial name
- NCT04509661
- Volunteers
- 200 people
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
Chronic Obstructive Pulmonary Disease (COPD)
A 12-week Treatment, Multi-center, Randomized, Double-blind, Parallel-group, Placebo and Active Controlled Study to Assess the Efficacy, Safety, and Tolerability of Indacaterol Maleate / Glycopyrronium Bromide in COPD Patients With Moderate to Severe Airflow Limitation
This study will assess the efficacy, safety and tolerability of indacaterol maleate/glycopyrronium bromide in patients with moderate to severe airflow limitation.
- Trial name
- NCT01712516
- Testing
- QVA149, QAB149, NVA237
- Where
- 95 sites in United States, Colombia and 7 more
- Volunteers
- 1,001 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Obstructive Pulmonary Disease
Correlation of Airflow Limitation and Other Respiratory Characteristics With Radiologic Changes of Lung Structure
The aim of the study is to assess the correlation between airflow limitation, perception of dyspnea and functional capacity with anatomic changes in pulmonary structure as seen on High Resolution CT in COPD patients.
- Trial name
- NCT00799305
- Where
- Israel
- Volunteers
- 30 people
- Sponsor
- Hillel Yaffe Medical Center
Chronic Obstructive Pulmonary Disease
Efficacy and Safety Study of QVA149 in COPD Patients
The purpose of this study is to demonstrate that the efficacy of the combination product QVA149 is similar to the efficacy of the combination product umeclidinium/vilanterol on a pre-specified endpoint of FEV1 AUC0-24h while…
- Trial name
- NCT02487446
- Testing
- QVA149, Umeclidinium/vilanterol
- Where
- 58 sites in United States
- Volunteers
- 357 people
- Sponsor
- Novartis Pharmaceuticals
Pulmonary Disease, Chronic Obstructive
Airflow Limitation in Cardiac Diseases in Europe
This is a cross-sectional, observational study, investigating the point prevalence of Airflow Limitation in current or former smokers with established ischemic heart disease.
- Trial name
- ALICE (NCT01485159)
- Testing
- Spirometry
- Where
- 15 sites in Belgium, France and 7 more
- Volunteers
- 3,000 people
- Sponsor
- GlaxoSmithKline
Chronic Obstructive Pulmonary Disease (COPD)
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
The purpose of the study is to provide long term safety data of NVA237. This study will assess the safety and tolerability of a single dose strength of NVA237.
- Trial name
- NCT01697696
- Testing
- NVA237, Long-acting beta 2-agonist (LABA)
- Where
- 61 sites in United States
- Volunteers
- 511 people
- Sponsor
- Novartis Pharmaceuticals
COPD (Chronic Obstructive Pulmonary Disease), COPD
Dupilumab in Type 2-Inflamed COPD Across the Full Spectrum of Airflow Limitation: An Italian Multicentre Retrospective Cohort Study
This multicentre retrospective cohort study describes lung function and patient-reported outcomes in adults with chronic obstructive pulmonary disease (COPD) and type 2 inflammation who received add-on dupilumab in routine…
- Conditions
- COPD (Chronic Obstructive Pulmonary Disease), COPD, Eosinophilia
- Trial name
- DUPICENTRO (NCT07788092)
- Testing
- Dupilumab
- Where
- 6 sites in Italy
- Volunteers
- 40 people
- Sponsor
- Azienda Ospedaliera di Perugia
Asthma-COPD Overlap Syndrome
A Non-interventional Study to Investigate the Current Situation of Asthma-COPD Overlap Syndrome in Patients Over Age 40 With Persistent Airflow Limitation in China
To investigate the distributions of the patients with ACOS, asthma and COPD over age 40 with chronic airflow limitation in China.
- Trial name
- NCT02600221
- Where
- 13 sites in China
- Volunteers
- 2,016 people
- Sponsor
- AstraZeneca
Asthma
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
The purpose of this study is to evaluate the site and mechanisms responsible for expiratory airflow limitation in chronic, treated, non-smoking, stable asthmatics with moderate to severe persistent expiratory airflow obstruction.
- Trial name
- NCT01225913
- Testing
- fluticasone/salmeterol in all asthmatics, budesonide/formoterol or fluticasone/salmeterol in all asthmatics
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Gelb, Arthur F., M.D.
Respiratory (Chronic Obstructive Pulmonary Disease)
Study for Assessing the Prevalence of Airflow Limitation in Outpatients With History of Smoking Attending Cardiology Clinics
Chronic Obstructive Pulmonary Disease (COPD) is a global health concern, associated with structural lung abnormalities causing persistent airflow limitation (AL) and often result from cigarette smoking.
- Trial name
- ALSAC (NCT07315958)
- Where
- 2 sites in Turkey (Türkiye)
- Volunteers
- 1,000 people
- Sponsor
- AstraZeneca
Alpha 1-Antitrypsin Deficiency
Phase III, Efficacy and Safety of "Kamada-AAT for Inhalation"
The goal of this clinical trial is to learn if AAT for inhalation, at a dose of 80 mg/day can slow the progression of lung disease in people who have lung disease caused by severe genetic deficiency in Alpha 1 Antitrypsin (AATD).
- Trial name
- InnovAATe (NCT04204252)
- Testing
- Alpha 1-Antitrypsin
- Where
- 9 sites in Belgium, Finland and 4 more
- Volunteers
- 98 people
- Sponsor
- Kamada, Ltd.
Chronic Obstructive Pulmonary Disease
A 12 Week Study of QVA149 Compared to Fluticasone/Salmeterol (Advair) for Treatment of COPD
Study is to show that QVA149 is superior to the standard of care, fluticasone/salmeterol, in patients with moderate to severe airflow limitation.
- Trial name
- NCT01860066
- Testing
- QVA149, fluticasone/salmeterol
- Where
- 31 sites in Argentina, Belgium and 3 more
- Sponsor
- Novartis Pharmaceuticals
Chronic Obstructive Pulmonary Disease
Safety and Efficacy of NVA237 as an add-on to Fixed Dose Combination LABA/ICS
This study is to evaluate if add-on treatment with inhaled NVA237 (50 µg) once daily (o.d.) via single-dose dry-powder inhaler (SDDPI) further improves lung function and health status and is well tolerated compared to placebo in…
- Trial name
- GLOW8 (NCT01757015)
- Testing
- NVA237
- Sponsor
- Novartis Pharmaceuticals
Chronic Obstructive Pulmonary Disease (COPD)
A 12 Week Treatment, Multi-center, Randomized, Double-blind, Parallel-group, Placebo and Active Controlled Study to Assess the Efficacy, Safety, and Tolerability of Indacaterol Maleate / Glycopyrronium Bromide in COPD Patients With Moderate to Severe Airflow Limitation.
This study will assess the efficacy, safety and tolerability of QVA149 in patients with moderate to severe airflow limitation.
- Trial name
- NCT01727141
- Testing
- QVA149, QAB149, NVA237
- Where
- 143 sites in United States, Canada and 6 more
- Volunteers
- 1,042 people
- Sponsor
- Novartis Pharmaceuticals
Asthma
Asthma Symptom Perception Study
Asthma affects 8% of the United States population ages >60 years and causes considerable harm: older adults are 4 times more likely to die from asthma and have twice the risk of hospitalization.
- Trial name
- ASP RCT (NCT06612294)
- Testing
- PEF Interventional Session, Control Sessions, Control Booster
- Where
- 2 sites in United States
- Volunteers
- 300 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Asthma
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
The purpose of this study is to evaluate the site and mechanisms responsible for expiratory airflow limitation in chronic, treated, non-smoking, stable asthmatics with moderate to severe persistent expiratory airflow obstruction.
- Trial name
- NCT00576069
- Testing
- budesonide/formoterol, fluticasone/salmeterol, mometasone/formoterol
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Gelb, Arthur F., M.D.
Asthma
Phosphodiesterase 4 Gene Variant and Salbutamol Response in Persistent Childhood Asthma
This study is designed to investigate whether the Phosphodiesterase 4 gene variability could be implicated in the salbutamol responsiveness in asthmatic children.
- Trial name
- PEGASE2 (NCT03592212)
- Testing
- Salbutamol
- Where
- France
- Volunteers
- 99 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Obesity
Expiratory Airflow Limitation in Subjects With Obesity
The purpose of this study is to investigate posture dependent small airway obstruction in subjects with obesity, and to study the capacity of FOT as a measurement tool for small airways obstruction.
- Trial name
- EFL (NCT00865293)
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Medical Center Alkmaar